Prostate cancer radioligand therapy: PSMA and beyond, current landscape and future directions Review
| Authors: | Bent, E. H.; Morris, M. J. |
| Review Title: | Prostate cancer radioligand therapy: PSMA and beyond, current landscape and future directions |
| Abstract: | Purpose of ReviewThere has been a rapid increase in the use and investigation of radioligand therapies for prostate cancer. This review summarizes and synthesizes the current prostate cancer radioligand landscape. It highlights the challenges facing optimal radioligand use and outlines approaches to improve the efficacy of this therapeutic class.Recent FindingsThe prostate specific membrane antigen (PSMA)-directed radioligand 177Lu-PSMA-617 improves survival in patients with metastatic castrate resistant prostate cancer (mCRPC) after chemotherapy and is now a standard of care treatment option for these patients. Published and ongoing trials promise to expand the use of radioligand therapies in prostate cancer. These trials highlight the potential of novel radioligand targets, alternate radioisotopes, and combination therapy approaches to improve radioligand efficacy.SummaryEmerging radioligands, novel combination therapies, optimized patient selection, and dose-personalization promise to improve outcomes and expand the use of radioligand therapies in prostate cancer. |
| Keywords: | radiotherapy; prostate cancer; membrane antigen; dosimetry; pet; phase-i trial; monoclonal-antibodies; radiation-therapy; multicenter; open-label; radioligand; psma; radiopharmaceutical; radium-223; theranostic; rlt |
| Journal Title: | Current Oncology Reports |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Publication status: | Online ahead of print |
| Date Published: | 2025-08-27 |
| Online Publication Date: | 2025-08-27 |
| Language: | English |
| ACCESSION: | WOS:001558727900001 |
| DOI: | 10.1007/s11912-025-01686-y |
| PROVIDER: | wos |
| PUBMED: | 40864353 |
| Notes: | Review; Early Access -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Michael Morris -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work